Nanoform and Pharmanovia to breathe new life into famous medicines

HelsinkiAnd the July 14, 2022 /PRNewswire/ – Nanoform Finland Plc. , an progressive firm enabling drugs with nanoparticles, in the present day introduced that it has partnered with Pharmanovia, a quickly rising specialty pharmaceutical firm with a portfolio of greater than 20 branded medicine in 140 markets.

The brand new strategic partnership goals so as to add worth to prescription medicines. Pharmanovia will look to use Nanoform’s proprietary nanoparticle applied sciences and formulation experience to main pharmaceutical manufacturers.

The partnership begins with a good drug the place each events see worth in enhancing bioavailability for the advantage of the affected person. Settlement worth restricted underneath the Nanoform enterprise mannequin for non-GMP and cGMP companies.

“This partnership is a superb instance of the place the ability of small companies can add worth to common prescribed drugs to make them simpler. Pharmanovia’s enterprise mannequin permits model loyalty to proceed from era to era.And the” He mentioned Christian JonesIndustrial Director of Nanoform Company.

For extra data, please contact:

Christian JonesCCO
[email protected] / +44 7804 474771

For investor relations inquiries, please contact:

Henry von HartmannInvestor Relations Supervisor
[email protected] / +46 7686650 11

About nanoform

Nanoform is an progressive firm within the discipline of nanoparticle drugs. Nanoform works hand in hand with pharmaceutical and biotechnology companions globally to supply hope to sufferers in creating new and improved medicines utilizing the applied sciences of the Nanoform platform. The corporate focuses on decreasing medical attrition and enhancing the efficiency of drug molecules by nanoforming applied sciences and formulation companies. Nanoform’s capabilities embrace GMP manufacturing, and its companies cowl the small to massive molecule growth house with a concentrate on fixing key issues in drug solubility and bioavailability and enabling new drug supply functions. Nanoform shares are listed within the Premier phase of the Nasdaq First North Progress Market in Helsinki (Inventory bar: NANOFH) and Stockholm (Inventory ticker: NANOFS). Licensed Marketing consultant: Danske Financial institution A/S, Finland Department, +358 40744 1900. For extra data, please go to

forward-looking statements

This firm launch incorporates forward-looking statements, together with, however not restricted to, statements concerning Nanoform’s technique, enterprise plans, and focus. The phrases could also be, “would,” “might,” “will,” “ought to,” “count on,” “plan,” “count on,” “intend,” “consider,” “estimate,” “predict,” “venture” and “potential.” and “proceed”, “goal” and comparable expressions are supposed to establish forward-looking statements, though not all forward-looking statements include such figuring out phrases.Any forward-looking statements on this Firm’s launch are based mostly on administration’s present expectations and beliefs and are topic to various important dangers, uncertainties and elements which will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements, together with, however not restricted to, any statements referring to Nanoform’s enterprise, operations, medical trials, provide chain, technique, and goals projected schedules and competitors from different corporations Nanoform cautions you to not place undue reliance on any forward-looking statements, which communicate solely as of the date they have been made Nanoform disclaims any obligation to publicly replace or revise any such statements to mirror any change in expectations or in Occasions, circumstances or situations which will such statements are based mostly on, or could have an effect on the chance that precise outcomes will differ from these said within the forward-looking statements. Any forward-looking statements contained on this firm launch characterize Nanoform’s views solely as of the date hereof and shouldn’t be relied upon as representing Nanoform’s views as of any later date.

This data was delivered to you by Cision, c3600995

The next recordsdata can be found for obtain:



View authentic content material:

nanoform supply